The future of cancer immunotherapy
In recent years, the incidence and mortality of cancer have been rising steadily. It not only brings infinite pain to the patients themselves and their families, but also causes serious social and economic problems. “Dying to Survive”this film was praised by the public as "zero bad review" before the release. It just reflects the degree of concern from the side.
In terms of treatment methods, traditionally, surgery usually uses "cutting", chemotherapy "toxic", radiotherapy and "burning". Later, scientists developed BRAF inhibitors, EGFR inhibitors and so on based on tumor mutation sites, thus opened the era of targeted drug therapy.
However, targeted therapy encounters two problems:
1. Patients have high expectations when doing mutational examinations, but they may not be able to find effective drugs.
2. Even with targeted drug therapy, many tumors, such as malignant melanoma and lung cancer, will develop resistance after a period of treatment.
Under such a circumstance, the development of tumor immunotherapy has attracted much attention and expectation in the industry. However, it also has problems that are only useful for some patients, and there are also cases where the combined effect of clinical research is not good. If we want to increase the patient's response to immunotherapy, the combination of drugs is the future direction. And the Biomarker is the key to combining the drugs. How to turn Biomarker from the detected data into usable information to guide drug development and clinical trials will be the future direction of tumor immunotherapy.
In terms of treatment methods, traditionally, surgery usually uses "cutting", chemotherapy "toxic", radiotherapy and "burning". Later, scientists developed BRAF inhibitors, EGFR inhibitors and so on based on tumor mutation sites, thus opened the era of targeted drug therapy.
However, targeted therapy encounters two problems:
1. Patients have high expectations when doing mutational examinations, but they may not be able to find effective drugs.
2. Even with targeted drug therapy, many tumors, such as malignant melanoma and lung cancer, will develop resistance after a period of treatment.
Under such a circumstance, the development of tumor immunotherapy has attracted much attention and expectation in the industry. However, it also has problems that are only useful for some patients, and there are also cases where the combined effect of clinical research is not good. If we want to increase the patient's response to immunotherapy, the combination of drugs is the future direction. And the Biomarker is the key to combining the drugs. How to turn Biomarker from the detected data into usable information to guide drug development and clinical trials will be the future direction of tumor immunotherapy.
